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Gene-expression profiling in childhood acute lymphoblastic leukaemia (ALL) was first done by Yeoh 
and colleagues
1
 at St Jude Children’s Research Hospital in Memphis, TN, USA, in 2002. Since then, 
many international paediatric ALL trial groups have incorporated genome-wide expression analyses 
into their studies.
2–5
 A key aim has been to identify novel predictors of outcome. However, due to 
the heterogeneity of childhood ALL and its rarity compared with most adult cancers, these studies 
have not identified robust and reproducible classifiers
6
 that are better than those in current clinical 
use: age, white blood-cell count, cytogenetics, morphological treatment response, and minimal-
residual-disease monitoring.  
 
In this issue of The Lancet Oncology, den Boer and colleagues
7 
describe a novel high-risk ALL subtype 
with a gene-expression profile that resembles Philadelphia chromosome-positive ALL—one that is 
not associated with any known risk factors. Philadelphia chromosome-positive ALL is a well 
recognised but rare poor-risk group of childhood ALL, characterised by abnormal signalling through 
the BCR-ABL1 fusion oncoprotein. Unlike many rare poor-risk groups, this new BCR-ABL1-like 
subtype comprises 15–20% of patients with ALL and includes many paediatric patients that will 
eventually relapse. If the subtype can be confirmed by other groups with different treatment 
protocols, this BCR-ABL1-like ALL will constitute a relevant and important study population for future 
clinical trials. In-vitro tests have shown that leukaemic blasts from these patients are significantly 
more resistant to asparaginase. The first clinical question to ask is whether it is possible to reduce 
relapses in this group by including patients in high-risk chemotherapy groups—ie, will the patients 
benefit from more intense treatment and can drug resistance be overcome in this subtype?  
 
The report of a new ALL subtype is an exciting find; however, the story is still incomplete. Without 
established diagnostic criteria, it is impossible to allocate these patients to specific treatment groups 
within clinical trials. A key issue will be to develop and validate a gene-expression classifier that can 
prospectively identify these patients. In the meantime, other international ALL trial groups should 
interrogate their data sets (using the 110 probe set-based gene-expression classifier described in this 
paper) to confirm the clinical significance of this new ALL subtype in relation to other known risk 
factors. In particular, it is important to analyse the role of minimal-residual disease monitoring in 
these BCR-ABL1-like patients and check whether it is possible to identify patients at very high risk 
who might benefit from allogenic stem-cell transplantation or those that might qualify for more 
experimental treatment strategies.  
 
The biggest challenge will be to unravel the biology that underlies this novel subtype. High 
resolution, genome-wide single-nucleotide polymorphism arrays did not identify a genomic 
alteration common to all patients. However, about 80% of the alterations had deletions involving B-
cell development genes, including the transcription factors IKZF1, TCF3, EBF1, and PAX5 as well as 
the pre-B-cell receptor surrogate light chain VPREB1. Den Boer and colleagues also describe IKZF1, 
PAX5, and VPREB1 deletions at high frequency in Philadelphia chromosome-positive ALL. Deletions 
in these genes are frequent in B-cell precursor ALL,
8,9
 and not restricted to Philadelphia 
chromosome-positive and BCR-ABL1-like ALL, so it is unlikely that these deletions are sufficient to 
explain the poor risk of this new ALL subtype and its similarities to Philadelphia chromosome-
positive ALL. An important approach will be to identify any common signalling pathways that are 
activated in both subtypes and novel therapeutic targets that could be explored by future clinical 
trials. Identification of common pathways will raise questions such as: are these pathways activated 
by mutations, by epigenetic regulation, or is it only the high frequency of deletions of B-cell 
development genes, in particular IKZF1, that make the two subtypes appear to be similar? Recent 
data by Mullighan and colleagues
10
 also demonstrate that alterations of IKZF1 are associated with a 
poor outcome and a BCR-ABL1-like transcription profile. Finally, is there heterogeneity in this 
subtype? At least some other poor-risk leukaemias, such as those with intrachromosomal 
amplification of chromosome 21 (iAMP21)
11
 or the dicentric chromosome, dic(9;20), are included 
within this subtype, albeit at low frequency. 
 
Despite unresolved questions, the study by den Boer and colleagues
7
 is important for showing how 
genome-wide expression arrays can help develop and improve molecular disease classification. This 
work will stimulate further research into the interesting new ALL subtype. Only once we understand 
the underlying biology, however, and can use this information for treatment allocation or the 
development of targeted therapy, will this subtype be relevant.  
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